Accidents hémorragiques des nouveaux anticoagulants oraux et examens de la coagulation

Weitz, 2012, New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 141, 120, 10.1378/chest.11-2294 Yoshida, 2013, Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin, Ann Vasc Surg, 27, 355, 10.1016/j.avsg.2012.06.010 Samama, 2011, Laboratory assessments of new anti-coagulants, Clin Chem Lab Med, 49, 761, 10.1515/CCLM.2011.134 Agnelli, 2013, Apixaban for extended treatment of venous thromboembolism, N Engl J Med, 368, 699, 10.1056/NEJMoa1207541 Samama, 2012, Do new oral anticoagulants require laboratory monitoring? The clinician point of view, Thromb Res, 130, S88, 10.1016/j.thromres.2012.08.286 Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 Eriksson, 2008, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty, N Engl J Med, 358, 2765, 10.1056/NEJMoa0800374 Schulman, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 The Executive Steering Committee, 2010, Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study, Am Heart J, 159, 340, 10.1016/j.ahj.2009.11.025 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Connolly, 2011, Apixaban in patients with atrial fibrillation, N Engl J Med, 364, 806, 10.1056/NEJMoa1007432 Samama, 2010, Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor, Thromb Haemost, 103, 815, 10.1160/TH09-03-0176 Gerotziafas, 2012, Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban, Thromb Res, 129, 101, 10.1016/j.thromres.2011.09.004 Mani, 2013, Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions, Thromb Haemost, 109, 127, 10.1160/TH12-04-0228 Lindhoff-Last, 2010, Assays for measuring rivaroxaban: their suitability and limitations, Ther Drug Monit, 32, 673, 10.1097/FTD.0b013e3181f2f264 Samama, 2007, Nouveaux anticoagulants, Ann Pharm Fr, 65, 85, 10.1016/S0003-4509(07)90021-8 Samama, 2011, Hétérogénéité pharmacologique des nouveaux anticoagulants, J Mal Vasc, 36, S10, 10.1016/S0398-0499(11)70002-6 Tripodi, 2011, The INR calibrated for rivaroxaban (INRivaroxaban) has the potential to normalize PT results for rivaroxaban-treated patients. Results of an in vitro study, J Thromb Haemost, 9, 226, 10.1111/j.1538-7836.2010.04106.x Harenberg, 2011, Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability, J Thromb Thrombolysis, 32, 267, 10.1007/s11239-011-0622-5 Samama, 2012, Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: the results of a multicenter field trial, Clin Appl Thromb Hemost, 18, 150, 10.1177/1076029611426282 Samama, 2012, Rivaroxaban anti-factor Xa chromogenic assay field trial laboratories. Evaluation of the anti Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls, Thromb Haemost, 107, 379, 10.1160/TH11-06-0391 Samama, 2013, Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study, J Thromb Thrombolysis, 35, 140, 10.1007/s11239-012-0803-x Freyburger, 2011, Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement, Thromb Res, 127, 457, 10.1016/j.thromres.2011.01.001 Mueck, 2008, Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement, Thromb Haemost, 100, 453, 10.1160/TH07-12-0714 Mueck, 2011, Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention, Clin Pharmacokinet, 50, 675, 10.2165/11595320-000000000-00000 Stangier, 2012, Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran, Blood Coagul Fibrinolysis, 23, 138, 10.1097/MBC.0b013e32834f1b0c Southworth, 2013, Dabigatran and postmarketing reports of bleeding, N Engl J Med, 368, 1272, 10.1056/NEJMp1302834 McConeghy, 2013, Reports of bleeding-related fatalities with dabigatran and warfarin: an analysis using the Food and Drug Administration adverse events reporting system, J Am Coll Cardiol, 61, 10_S, 10.1016/S0735-1097(13)60319-8 Harinstein, 2012, Treatment of dabigatran-associated bleeding: case report and review of the literature, J Pharm Pract Holster, 2013, New oral anticoagulants increase risk for gastrointestinal bleeding–A systematic review and meta-analysis, Gastroenterology, 10.1053/j.gastro.2013.02.041 Harper, 2012, Bleeding risk with dabigatran in the frail elderly, N Engl J Med, 366, 864, 10.1056/NEJMc1112874 Legrand, 2011, The use of dabigatran in elderly patients, Arch Intern Med, 171, 1285, 10.1001/archinternmed.2011.314 Husari, 2013, The untold story of dabigatran etexilate; alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis, J Thromb Thrombolysis, 35, 81, 10.1007/s11239-012-0784-9 Barton, 2012, Hemopericardium in a patient treated with dabigatran etexilate, Pharmacotherapy, 32, e103, 10.1002/j.1875-9114.2012.01036.x Cano, 2012, Clinical challenges in a patient with dabigatran-induced fatal hemorrhage, Am J Geriatr Pharmacother, 10, 160, 10.1016/j.amjopharm.2012.02.004 Mastrobuoni, 2012, Spontaneous ascending aortic intramural haematoma in a patient on dabigatran, Interact Cardiovasc Thorac Surg, 15, 299, 10.1093/icvts/ivs220 Wychowski, 2012, Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment, Ann Pharmacother, 46, 10.1345/aph.1Q747 Chen, 2012, Hemorrhagic complications associated with dabigatran use, Clin Toxicol (Phila), 50, 854, 10.3109/15563650.2012.721888 Dy, 2012, Hemopericardium and cardiac tamponade associated with dabigatran use, Ann Pharmacother, 46, e18, 10.1345/aph.1R112 Dumkow, 2012, Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma, Am J Health Syst Pharm, 69, 1646, 10.2146/ajhp120055 Fellows, 2013, Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency, J Emergency Med, 44, e221, 10.1016/j.jemermed.2012.02.042 Lillo-Le Louët, 2012, Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: complications for emergency surgery and resuscitation, Thromb Haemost, 108, 583, 10.1160/TH12-03-0149 Moore, 2012, Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation, Am J Emerg Med, 30, 10.1016/j.ajem.2011.10.031 Aron, 2013, Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-association intracranial hemorrhage, J Thromb Thrombolysis, 10.1007/s11239-013-0913-0 Garber, 2012, Neurosurgical complications of direct thrombin inhibitors–catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran, J Neurosurg, 116, 1093, 10.3171/2012.2.JNS112132 Saignement sous dabigatran, rivaroxaban ou apixaban. Pas d’antidote et peu d’expérience clinique. Prescrire 2013; 353:202–6. Woo, 2013, Positive outcome after intentional overdose of dabigatran, J Med Toxicol, 9, 192, 10.1007/s13181-012-0276-5 Boland, 2012, Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: a case report, J Med Case Reports, 6, 129, 10.1186/1752-1947-6-129 Jameson, 2012, Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty, J Bone Joint Surg Am, 94, 1554, 10.2106/JBJS.K.00521 Van Ryn, 2013, Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment), AHA Lu, 2013, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nat Med, 19, 446, 10.1038/nm.3102 Marlu, 2012, Reversal of anticoagulant effect of dabigatran and rivaroxaban by non-specific reversal agents: a randomized crossover ex vivo study in healthy volunteers, Thromb Haemost, 108, 217, 10.1160/TH12-03-0179 Levi, 2012, Reverse engineering for new oral anticoagulants: non specific reversal agents and the anticoagulants activity of dabigatran and rivaroxaban, Thromb Haemost, 108, 201, 10.1160/TH12-05-0330 Wanek, 2012, Safe use of hemodialysis for dabigatran removal before cardiac surgery, Ann Pharmacother, 46, e21, 10.1345/aph.1R081 McLellan, 2013, Dabigatran elimination: is hemodialysis effective?, Thromb Haemost, 109, 580, 10.1160/TH13-01-0064 Khadzhynov, 2013, Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease, Thromb Haemost, 109, 596, 10.1160/TH12-08-0573 Van Ryn, 2009, Absorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro, ASH Sie, 2011, Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin of factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis, Arch Cardiovasc Dis, 104, 669, 10.1016/j.acvd.2011.09.001 Douxfils, 2012, Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature, Thromb Res, 130, 956, 10.1016/j.thromres.2012.09.004 Lee, 2012, Intravenous thrombolysis in a stroke patient taking dabigatran, J Stroke Cerebrovasc Dis, 21, 10.1016/j.jstrokecerebrovasdis.2012.04.008 Healey, 2012, Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin, Circulation, 126, 343, 10.1161/CIRCULATIONAHA.111.090464